Neurol. pro Praxi, 2002; 2: 101-105 [Psychiatr. pro Praxi, 2002; 2: 55-58]

Současné trendy v kognitivní farmakoterapii Alzheimerovy choroby

doc. MUDr. Roman Jirák, CSc.
Psychiatrická klinika 1. LF UK a VFN Praha

Keywords: Alzheimerova choroba, inhibitory acetylcholinesterázy, nootropika, scavengery volných radikálů, blokátory kalciových kanálů, nervové růstové faktory.

Published: December 31, 2002  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jirák R. Současné trendy v kognitivní farmakoterapii Alzheimerovy choroby. Neurol. praxi. 2002;3(2):101-105.

Kognitivní farmakoterapie Alzheimerovy choroby se snaží o ovlivnění základních známých etiopatogenetických článků nemoci. Nejvíce je v současnosti zaměřena pozornost na zlepšení centrální acetylcholinergní transmise. Jsou používány především inhibitory acetylcholinesteráz, které představují léky první volby u lehkých až středních případů Alzheimerovy choroby. Tato léčba je dále doplňována řadou přístupů, které jsou teoreticky zdůvodnitelné, v praxi však často nemusí mít výraznější efekt, nejsou to vždy přístupy, odpovídající -evidence based- medicíně. Je zmíněno použití látek, zlepšujících mozkový metabolizmus, vychytávajících volné kyslíkové radikály, zlepšujících výdej nervových růstových hormonů, ovlivňujících zánětlivé změny mozku, snižujících nadměrný influx kalcia do neuronů.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Alom J, Lebluher F, Cras P, Yener G, Jirák R, Korczyn A, Turcani P. The donepezil global 322 study group: Donepezil for the treatment of Alzheimer´s disease: A multinational clinical experience study. Internat Psychogeriat 2001 (Suppl. 2): 245.
    2. Birge SJ. The role of estrogen in the treatment of Alzheimer´s disease. Neurology 1997; 48 (Suppl. 7): 36-41. Go to original source... Go to PubMed...
    3. Blesa R. Galantamine: therapeutic effects beyond cognition. Dement Geriat Cogn Disord 2000; 11 (Suppl. 1): 28-34. Go to original source... Go to PubMed...
    4. Doody RS, Stevens JC, et al.: Practice parameter: Management of dementia (an evidence-based review). Report of the Quality standards subcomittee of the American Academy of Neurology. Neurology 2000; 56: 1154-1166. Go to original source... Go to PubMed...
    5. Evans DA, Morris MC. Is a randomizedtrial of antioxidants in the primary prevention of Alzheimer disease warranted? Alzheimer. Dis Assoc Disord 1996; 10 (Suppl. 10): 45-49. Go to original source... Go to PubMed...
    6. Isackson PJ, Murray KD. Neurotrophic factors in the treatment of Alzheimer´s disease. DN§P 7 1994; (10): 585-592.
    7. Le Bars P, Katz MM, Berman A, et al. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA 1997, 278, 1327-1332. Go to original source...
    8. McKeith I, Del Ser T, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. The Lancet 2000; 9247: 2031-2036. Go to original source... Go to PubMed...
    9. Meldrum BS. Anti-excitatory amino acid approach in the treatment of neurodegenerative disorders. Europ. Neuropsychopharm 1993; 3: 184-185. Go to original source...
    10. Robbins TW, McAlonan G, Muir JL, Everitt BJ. Cognitive enhancers in therapy and practice: studies of cholinergic hypothesis of cognitive deficits in Alzheimer´s disease. Behav Brain Res 1997; 83 (1-2): 15-23. Go to original source... Go to PubMed...
    11. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer´s disease. Donepezil study group. Neurology 1998; 50: 136-145. Go to original source... Go to PubMed...
    12. Rösler M, Retz W, Retz-Junginger P, Dennler HJ. Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer´s disease. Behav. Neurology 1998/99; 11: 211-216. Go to original source... Go to PubMed...
    13. Rother M. Propentophylline versus placebo in patients with Alzheimer´s disease. AAN 51st Annual Meeting, Toronto, Canada, Apr. 1999: 17-24.
    14. Rüther E, et al. Efficacy of the peptidergic nootropic drug Cerebrolysin in patients with senile dementia of the Alzheimer type. Pharmacopsychiatry, 1994; 1: 34-40. Go to original source... Go to PubMed...
    15. Sano M, et al. A controlled trial of selegiline, alpha-tocoferol, or both as treatment for Alzheimer´s disease. The Alzheimer´s disease cooperative study. N Engl J Med 1997; 336: 1216-1222. Go to original source... Go to PubMed...
    16. Scott LJ, Goa KL. Galantamine: A review of its use in Alzheimer´s disease. Drugs 2000; 60: 1095-1122. Go to original source... Go to PubMed...
    17. Yamada K, et al. Orally active NGF synthesis stimulators: Potentialtherapeutic agents in Alzheimer´s disease. Behav Brain Res 1997; 83 (1-2): 117-122. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.